RNA FY2025Q3 Net Loss Increased by 76.4% Compared to Prior Year

Executive Summary

This comprehensive financial report analyzes Avidity Biosciences, Inc. (NASDAQ: RNA) for the third quarter of fiscal year 2025. The company reported a net loss of $447.5 million, representing a 76.4% increase compared to the net loss of $220.0 million in the same period last year. The significant deterioration in net income reflects increased operating expenses and ongoing R&D investments amid a robust cash position of $350.2 million, supporting strategic growth and upcoming merger activities.

Management Discussion and Analysis

During Q3 FY2025, Avidity Biosciences continued to prioritize research and development, incurring $154.9 million in R&D expenses, a 25.7% increase from $123.2 million in Q3 FY2024. Administrative costs also rose to $46.3 million, up 100.0% from $23.2 million, primarily due to increased administrative activities related to upcoming corporate transactions. The company’s total operating expenses reached $201.3 million, a 100.2% increase YoY, driven by strategic investments in pipeline development and infrastructure expansion. Cash and marketable securities totaled $1.5 billion, providing ample liquidity for ongoing operations and merger-related activities.

Income Statement Analysis

Revenue and Gross Profit

Collaboration revenue for Q3 FY2025 was $12.5 million, a 434.4% increase from $2.3 million in Q3 FY2024, mainly due to milestone payments from Lilly and BMS collaborations. Gross profit margins are not explicitly provided but are expected to be low given the company’s early-stage R&D focus.

Operating Income and Net Loss

The company reported a net loss of $447.5 million, a 103.4% increase from $220.0 million in the same quarter last year. The loss per share was $3.38, compared to $2.08 in Q3 FY2024. The YoY increase is primarily attributable to higher operating expenses and increased stock-based compensation costs.

EPS and Trends

Basic and diluted net loss per share increased from $0.65 in Q3 FY2024 to $3.38 in Q3 FY2025, reflecting the expanded operational scale and ongoing investments.

Balance Sheet Analysis

Assets and Liquidity

As of September 30, 2025, total assets stood at $2.13 billion, up 36.5% from $1.56 billion at year-end 2024. Cash and cash equivalents increased by 59.4% to $350.2 million, while marketable securities grew by 18.8% to $1.525 billion. The company’s current assets totaled $1.97 billion, providing strong liquidity for future needs.

Liabilities and Equity

Total liabilities increased to $247.9 million from $138.9 million, mainly due to lease liabilities and deferred revenue. Stockholders’ equity rose significantly to $1.89 billion, driven by accumulated deficit reduction and capital raises. The company’s debt levels remain minimal, supporting a low leverage profile.

Cash Flow Analysis

Net cash used in operating activities was $480.7 million, primarily due to net losses and increased working capital investments. Cash flows from investing activities were negative at $245.3 million, mainly from purchases of marketable securities. Financing activities generated $856.1 million, driven by a public offering of 17.25 million shares at $40 per share, netting approximately $651.4 million after expenses. The company maintains a strong cash position to fund ongoing R&D and merger activities.

Ratios & DuPont Analysis

Given the net loss of $447.5 million and total assets of $2.13 billion, the estimated return on assets (ROA) is approximately -21.0%. The net profit margin is -21.0%, indicating high R&D and administrative expenses. The equity multiplier is approximately 1.13, reflecting low leverage. The company’s ROE is estimated at -23.7%, highlighting the early-stage nature and significant investments.

Risk Factors

Key risks include regulatory delays in clinical trials, market competition from other RNA therapeutics, operational risks related to merger integration, and macroeconomic factors affecting capital markets. The company’s substantial R&D investments and ongoing merger activities also pose execution risks.

Notes & Additional Commentary

Unusual items include a significant increase in stock-based compensation and lease liabilities related to new office facilities. The upcoming merger with Novartis and spin-off of certain assets are expected to impact future financial statements and strategic direction. No material litigation liabilities are currently reported.

Investment Implications

Short-term opportunities include capital raised through equity offerings, providing liquidity for pipeline advancement. Long-term risks involve execution of merger plans, regulatory approvals, and market acceptance of novel RNA therapeutics. The company’s strong cash position and strategic collaborations support a cautiously optimistic outlook, with a focus on pipeline development and corporate restructuring.